Review
Engineering, Biomedical
Yu Chen, Yue Pan, Danrong Hu, Jinrong Peng, Ying Hao, Meng Pan, Liping Yuan, Yongyang Yu, Zhiyong Qian
Summary: Cabazitaxel, a second-generation taxane, shows potential to overcome taxane resistance but its clinical use is restricted due to high systemic toxicity, hydrophobicity, and instability. Nanomedicine is believed to offer solutions to these limitations and help surmount taxane resistance.
BIOMEDICAL MATERIALS
(2021)
Article
Biochemistry & Molecular Biology
Lina Liu, Mengyuan Li, Junshuo Zhang, Dengfei Xu, Yan Guo, Hui Zhang, Shundong Cang
Summary: This study reveals the cross-resistance between docetaxel and cabazitaxel in castration-resistant prostate cancer (CRPC) and identifies KIF14 as the main cause. Silencing KIF14 expression can restore sensitivity to these drugs, inhibit cell proliferation, and promote apoptosis. Targeting KIF14 may enhance the effectiveness of docetaxel or cabazitaxel chemotherapy.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
(2023)
Article
Materials Science, Multidisciplinary
Yu Chen, Yi Lu, Danrong Hu, Jinrong Peng, Yao Xiao, Ying Hao, Meng Pan, Liping Yuan, Zhiyong Qian
Summary: Colorectal cancer ranks third in men and second in women, with no consensus on standard treatments. Cabazitaxel shows promise in treating colorectal cancer, but its adverse effects and poor stability led researchers to synthesize a new block copolymer for nanoparticle formulations to enhance its efficacy. The new nanoparticle preparations have shown improved drug loading, stability, and antitumor efficacy, with reduced toxicity, indicating high safety and great potential in colorectal cancer therapy.
APPLIED MATERIALS TODAY
(2021)
Review
Biochemistry & Molecular Biology
Yu Wu, Yingqiu Song, Runze Wang, Tianlu Wang
Summary: In this review, the crucial factors causing resistance of cancer to radiation therapy have been extensively discussed, including radiation-induced DNA damage repair, cell cycle arrest, apoptosis escape, abundance of cancer stem cells, modification of cancer cells and their microenvironment, presence of exosomal and non-coding RNA, metabolic reprogramming, and ferroptosis. The aim is to focus on the molecular mechanisms of cancer radiotherapy resistance and discuss possible targets to improve treatment outcomes.
Article
Medicine, General & Internal
Eric Wang, Xiaoli Mi, Meghan C. Thompson, Skye Montoya, Ryan Q. Notti, Jumana Afaghani, Benjamin H. Durham, Alex Penson, Matthew T. Witkowski, Sydney X. Lu, Jessie Bourcier, Simon J. Hogg, Caroline Erickson, Dan Cui, Hana Cho, Michael Singer, Tulasigeri M. Totiger, Sana Chaudhry, Mark Geyer, Alvaro Alencar, Adam J. Linley, M. Lia Palomba, Catherine C. Coombs, Jae H. Park, Andrew Zelenetz, Lindsey Roeker, Mary Rosendahl, Donald E. Tsai, Kevin Ebata, Barbara Brandhuber, David M. Hyman, Iannis Aifantis, Anthony Mato, Justin Taylor, Omar Abdel-Wahab
Summary: This study reveals new mutations in the BTK kinase domain and occasional mutations in downstream PLC gamma 2 in patients with chronic lymphocytic leukemia who developed resistance to the noncovalent BTK inhibitor pirtobrutinib. Despite the inactivity of BTK, alternative pathways of B-cell-receptor signaling were evident.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Plant Sciences
Ying Wu, William Sexton, Bing Yang, Shunyuan Xiao
Summary: Nonhost resistance (NHR) in plants refers to the immunity of most tested genotypes of a plant species against most tested variants of a pathogen species. NHR is a broad spectrum and durable defense mechanism that serves as a major barrier against potentially pathogenic microbes invading plants. Through genetic studies, researchers have made significant progress in understanding the molecular basis of NHR, which includes pathogen-associated molecular pattern-triggered immunity and effector-triggered immunity. This review discusses the challenges in genetic studies of NHR and summarizes the approaches used to identify genes contributing to NHR, with a focus on dissecting multilayered NHR in model plants against filamentous pathogens.
MOLECULAR PLANT PATHOLOGY
(2023)
Article
Pharmacology & Pharmacy
Tongyu Li, Xiaona Chen, Jianqin Wan, Xiaoxiao Hu, Wanzhi Chen, Hangxiang Wang
Summary: This study demonstrates that combining cabazitaxel nanotherapeutics with a pan-Akt inhibitor MK-2206 sensitizes resistant cancer cells, reduces systemic toxicity, and maximizes efficacy in vitro and in an animal model. The nanoparticle formulation also shows higher tolerance compared to free cabazitaxel agent.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Review
Oncology
Neal S. Akhave, Amadeo B. Biter, David S. Hong
Summary: KRAS mutations drive cancer growth, but the development of resistance to targeted therapies remains a challenge. Understanding the mechanisms of resistance and developing combination strategies are crucial for long-term disease control.
Article
Plant Sciences
Feng Zhou, Ye-Xian Cui, Bing-Li Wang, Yu-Dong Zhou, Shi-Wang Li, Yan-Tong Zhang, Ke Zhang, Ze-Yuan Chen, Hai-Yan Hu, Cheng-Wei Li
Summary: Fusarium crown rot (FCR), caused by Fusarium pseudograminearum, is a significant disease in wheat production in the Huanghuai wheat-growing region of China. Fludioxonil, a phenylpyrrole fungicide, has not been registered for FCR control in China. This study identified four fludioxonil-resistant mutants of F. pseudograminearum and found that they exhibited reduced growth, sporulation, and pathogenicity. Molecular analysis showed that these mutants did not possess the characteristic amino acid changes associated with fludioxonil resistance in other species. The study also revealed cross-resistance between fludioxonil and cyprodinil, tebuconazole, and difenoconazole.
Article
Agriculture, Multidisciplinary
Yu Liu, Yang Sun, Yang Bai, Xin Cheng, Hui Li, Xing Chen, Yu Chen
Summary: This study investigated the resistance of the rice bakanae disease pathogen, F. fujikuroi, to the novel succinate dehydrogenase inhibitor Pydiflumetofen (Pyd). Through the generation of resistant mutants, different levels of resistance were identified, along with specific genotypes associated with resistance. The study suggests that the risk of resistance to Pyd in F. fujikuroi is moderate and comes with significant fitness cost.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
(2023)
Article
Urology & Nephrology
Di Maria Jiang, Nazanin Fallah-Rad, Roy Lee, Pamela Ng, Alan D. Smith, Aaron R. Hansen, Anthony M. Joshua, Jaclyn Beca, Srikala S. Sridhar
Summary: By cohorting patients receiving cabazitaxel on the same weekday, drug wastage and associated costs were significantly reduced, leading to a cost saving of $394 536 CAD (21.1%) over a 3-year period. Similar strategies could potentially be implemented to mitigate the financial burden associated with drug wastage for cabazitaxel and other oncology drugs.
Article
Oncology
Ariunbold Natsagdorj, Kouji Izumi, Kaoru Hiratsuka, Renato Naito, Suguru Kadomoto, Hiroaki Iwamoto, Hiroshi Yaegashi, Kazuyoshi Shigehara, Hiroki Nakata, Atsushi Mizokami
Summary: Resistance to cabazitaxel is a major challenge in CRPC patients. CCL2 induces resistance to the antimigration effect of cabazitaxel by inhibiting STAT3 and activating AKT. Targeting the CCL2-CCR2 axis may be a potential therapeutic strategy against chemoresistant CRPC.
ANTICANCER RESEARCH
(2023)
Article
Microbiology
Yiyun Chen, Josephine C. Moran, Stuart Campbell-Lee, Malcolm J. Horsburgh
Summary: Research has found that sphingosine resistance may be related to the regulation of genes such as SaeSR, VraSR, and CtsR, and there is a possibility of increasing sphingosine resistance through gene mutations. This is of great significance for studying the colonization of staphylococci on skin rich in sphingosine and topical therapeutic applications.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Review
Oncology
Louise Marchandet, Morgane Lallier, Celine Charrier, Marc Baud'huin, Benjamin Ory, Francois Lamoureux
Summary: Osteosarcoma is the most common primary bone tumor affecting children and adolescents, with resistance being one of the reasons for treatment failure. Understanding the molecular mechanisms of resistance is key to developing new strategies to improve patient outcomes.
Review
Oncology
Victoria Dunnett-Kane, Pantelis Nicola, Fiona Blackhall, Colin Lindsay
Summary: KRAS is a commonly mutated gene in cancer, but efforts to create direct inhibitors have largely failed until recent subtype specific inhibitors have shown promise. G12C inhibitors have entered clinical trials and shown early evidence of efficacy in patients, but there are concerns about potential drug resistance.
Article
Biochemistry & Molecular Biology
John C. Rose, Po-Ssu Huang, Nathan D. Camp, Jordan Ye, Andrew M. Leidal, Inna Goreshnik, Bridget M. Trevillian, Miles S. Dickinson, Daniel Cunningham-Bryant, Jayanta Debnath, David Baker, Alejandro Wolf-Yadlin, Dustin J. Maly
NATURE CHEMICAL BIOLOGY
(2017)
Article
Biochemical Research Methods
John C. Rose, Jason J. Stephany, William J. Valente, Bridget M. Trevillian, Ha V. Dang, Jason H. Bielas, Dustin J. Maly, Douglas M. Fowler
Article
Biochemical Research Methods
Xin Wang, Camille Terfve, John C. Rose, Florian Markowetz
Article
Chemistry, Multidisciplinary
Daniel Cunningham-Bryant, Emily M. Dieter, Glenna W. Foight, John C. Rose, Dana E. Loutey, Dustin J. Maly
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2019)
Article
Multidisciplinary Sciences
John C. Rose, Nicholas A. Popp, Christopher D. Richardson, Jason J. Stephany, Julie Mathieu, Cindy T. Wei, Jacob E. Corn, Dustin J. Maly, Douglas M. Fowler
NATURE COMMUNICATIONS
(2020)
Article
Multidisciplinary Sciences
King L. Hung, Kathryn E. Yost, Liangqi Xie, Quanming Shi, Konstantin Helmsauer, Jens Luebeck, Robert Schopflin, Joshua T. Lange, Rocio Chamorro Gonzalez, Natasha E. Weiser, Celine Chen, Maria E. Valieva, Ivy Tsz-Lo Wong, Sihan Wu, Siavash R. Dehkordi, Connor V. Duffy, Katerina Kraft, Jun Tang, Julia A. Belk, John C. Rose, M. Ryan Corces, Jeffrey M. Granja, Rui Li, Utkrisht Rajkumar, Jordan Friedlein, Anindya Bagchi, Ansuman T. Satpathy, Robert Tjian, Stefan Mundlos, Vineet Bafna, Anton G. Henssen, Paul S. Mischel, Zhe Liu, Howard Y. Chang
Summary: Extrachromosomal DNA (ecDNA) hubs are clusters of ecDNAs within the nucleus that enable intermolecular enhancer-gene interactions, promoting oncogene overexpression. The protein-tethered ecDNA hubs facilitate intermolecular transcriptional regulation, serving as units of oncogene function and potential targets for cancer therapy.
Article
Genetics & Heredity
Joshua T. Lange, John C. Rose, Celine Y. Chen, Yuriy Pichugin, Liangqi Xie, Jun Tang, King L. Hung, Kathryn E. Yost, Quanming Shi, Marcella L. Erb, Utkrisht Rajkumar, Sihan Wu, Sabine Taschner-Mandl, Marie Bernkopf, Charles Swanton, Zhe Liu, Weini Huang, Howard Y. Chang, Vineet Bafna, Anton G. Henssen, Benjamin Werner, Paul S. Mischel
Summary: Random segregation of extrachromosomal DNA contributes to intratumoral heterogeneity and facilitates the rapid adaptation of human tumor cells to anticancer drugs. Oncogene amplification on extrachromosomal DNA (ecDNA) is a common event, driving aggressive tumor growth, drug resistance and shorter survival. Through theoretical models, unbiased image analysis, CRISPR-based ecDNA tagging with live-cell imaging and CRISPR-C, it is shown that random ecDNA inheritance results in extensive intratumoral ecDNA copy number heterogeneity and rapid adaptation to metabolic stress and targeted treatment.
Meeting Abstract
Oncology
Jason Z. Zhang, William H. Nguyen, John C. Rose, Shao-En Ong, Dustin J. Maly, David Baker
MOLECULAR CANCER RESEARCH
(2023)
Meeting Abstract
Biochemistry & Molecular Biology
Emily M. Dieter, John Rose, Dustin Maly
Meeting Abstract
Health Care Sciences & Services
Charles P. Crooks, Christopher Ghiathi, John C. Rose, Jeffrey Redinger
JOURNAL OF GENERAL INTERNAL MEDICINE
(2018)
Article
Biochemistry & Molecular Biology
John C. Rose, Jason J. Stephany, Cindy T. Wei, Douglas M. Fowler, Dustin J. Maly
ACS CHEMICAL BIOLOGY
(2018)
Meeting Abstract
Oncology
John Rose, George Duran, Branimir Sikic